04.26.19

New Scientific And Clinical Analyses Regarding Bausch + Lomb Surgical And Pharmaceutical Products To Be Presented ARVO

Source: Bausch + Lomb

Bausch + Lomb announced that researchers will present the results of nine new scientific and clinical analyses involving the company’s pharmaceutical and surgical products, as well as data from the company’s Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillance study, during the Association for Research in Vision and Ophthalmology (ARVO) meeting in Vancouver, British Columbia (Apr. 28 – May 2, 2019).

The scientific posters will feature integrated data from three phase 3 multicenter, randomized, double-masked clinical trials on the proportion of subjects achieving zero-trace anterior chamber inflammation with the company’s new submicron loteprednol formulation, Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, following cataract surgery, as well as pooled data from three multicenter, randomized clinical studies analyzing the incidence of polybacterial infections in bacterial conjunctivitis and outcomes using besifloxacin ophthalmic suspension 0.6%.

Other poster presentations will include an assessment utilizing the eyeTELLIGENCE platform on the Stellaris Elite vision enhancement system to measure the relative effect of gauge size and surgeon efficiency during vitrectomy surgeries, as well as research regarding future IOL designs, next-generation delivery systems and product enhancements.

The ARMOR study analyses will include a 10-year trend analysis, examining antibiotic resistance trends among staphylococcal isolates collected in the ARMOR study to date, as well as a preliminary analysis of the 2018 ARMOR results. Initiated in 2009, the ARMOR surveillance study is the only ongoing multicenter survey of antibiotic resistance patterns specific to ocular pathogens in the United States that allows eye care professionals to track in vitro susceptibility rates for commonly used antibiotics.

The complete schedule (by date) for all poster presentations is as follows:

Sunday, April 28

  • Abstract Number: B0364, Blondeau, J.M. et al. “Incidence of Polybacterial Infections in Three Bacterial Conjunctivitis Studies and Outcomes with Besifloxacin Ophthalmic Suspension 0.6%.” Sunday, April 28 from 8:00 – 9:45 a.m.
  • Abstract Number: B0365, Sanfilippo, C et al. “Antibiotic Resistance Among Ocular Pathogens – An Update from the 2018 ARMOR Study.” Sunday, April 28 from 8:00 – 9:45 a.m.
  • Abstract Number: B0370, Martel, J et al. “Proportion of subjects achieving zero-trace anterior chamber inflammation with loteprednol etabonate (submicron) gel 0.38% following cataract surgery: Integrated analysis of 3 pivotal trials.” Sunday, April 28 from 8:00 – 9:45 a.m.
  • Abstract Number: B0331, Asbell, P et al. “Longitudinal Trends in Antibiotic Resistance Among Staphylococci Collected in the ARMOR Study.Sunday, April 28 from 1:00 – 2:45 p.m.
  • Abstract Number: A0462, Lau, G et al. “Comparison of Delivery Forces and Wound Dimensions of New Smaller Incision Injector for Plate-Haptic Intraocular Lens.” Sunday, April 28 from 1:00 – 2:45 p.m.

Tuesday, April 30

  • Abstract Number: B0233, Guenthner, G et al. “Evaluation of the Posterior Optic Square Edge Profile of Hydrophillic Acrylic Intraocular Lenses after Tumble Polishing with a Protective Mask.” Tuesday, April 30 from 11:45 – 1:30 p.m.
  • Abstract Number: B0237, Cook, M et al. “Ex vivo Optical Performance of Two Distinct Aberration-Neutral Monofocal IOL Designs.” Tuesday, April 30 from 11:45 – 1:30 p.m.
  • Abstract Number: B0245, Pilon, A et al. “Comparative Assessment of Outward Radial Forces Exerted by Hydrophobic Acrylic Intraocular Lenses and Capsular Tension Rings Under Common Degrees of Compression.” Tuesday, April 30 from 11:45 – 1:30 p.m.

Thursday, May 2

  • Abstract Number: B0247, Karthik, N et al. “Evaluating Ophthalmic Surgical Efficiency through the Stellaris® Platform: The Impact of Surgeon Volume and Gauge Size on Pars Plana Vitrectomy.” Thursday, May 2 from 8:00 – 9:45 a.m.

 

Related Content

01.30.19

Bausch Health Reduces Debt By Additional $100 Million

Source: Bausch Health Companies

04.03.19

ARVO Foundation Announces New Mallinckrodt Uveitis Research Fellowship

Source: Association for Research in Vision and Ophthalmology